The diabetes-associated excess risk of cardiovascular diseases is known to be higher in women than in men. Find out more in the article

Fixed-ratio combinations, the co-administration of two injectable therapies in a formulation that can be adjusted through titration, are changing the…

Positive renal effects of vildagliptin have been shown by several experimental studies.1,2 Nonetheless, clinical evidence for its renoprotective…

Advances in treatment offerings are moving beyond classical considerations around glucose control to focus on other aspects of the disease.

The current ‘Western cluster’ of non-communicable disorders could be redefined as a dysfunction of the heterogenic, complex, and bidirectional metabolic…

Hypertension is considered a powerful cardiovascular risk factor and is present in up to two-thirds of patients who suffer from diabetes. In the…

Diabetic macular oedema (DMO) is the leading cause of vision loss in working aged individuals. Macular laser photocoagulation was the primary DMO…

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors have complementary mechanisms of action.

The efficacy of probiotics in diabetes has been proven by their ability to lower fasting glucose and insulin levels in a preclinical setting as well as in human trials.

Higher BMI is associated with an adverse metabolic effect and a higher risk of Type 2 diabetes mellitus (T2DM), heart disease, and hypertension. However…